Quest Partners LLC Trims Position in Zoetis Inc. (NYSE:ZTS)

Quest Partners LLC lowered its position in Zoetis Inc. (NYSE:ZTS) by 77.4% in the second quarter, HoldingsChannel reports. The firm owned 2,427 shares of the company’s stock after selling 8,308 shares during the period. Quest Partners LLC’s holdings in Zoetis were worth $421,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Webster Bank N. A. grew its stake in shares of Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the period. Private Wealth Management Group LLC purchased a new position in Zoetis in the fourth quarter worth approximately $33,000. Neo Ivy Capital Management purchased a new position in Zoetis in the fourth quarter worth approximately $40,000. LRI Investments LLC acquired a new stake in Zoetis during the first quarter worth $43,000. Finally, Blue Bell Private Wealth Management LLC lifted its stake in shares of Zoetis by 111.6% in the 1st quarter. Blue Bell Private Wealth Management LLC now owns 273 shares of the company’s stock valued at $46,000 after purchasing an additional 144 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent analyst reports. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. BTIG Research boosted their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $200.00 target price on shares of Zoetis in a report on Tuesday, August 27th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $217.11.

Zoetis Price Performance

Zoetis stock opened at $191.17 on Friday. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The firm has a market cap of $87.23 billion, a PE ratio of 36.83, a price-to-earnings-growth ratio of 2.91 and a beta of 0.88. The company’s 50 day moving average is $182.85 and its two-hundred day moving average is $174.50.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. The business had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period last year, the firm earned $1.41 earnings per share. On average, research analysts expect that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.